Manufacturing News of Note—Aurobindo gets 2 483s; Catalent to make BeiGene drug

stocks
(Pixabay)

> The FDA recently posted two Form 483s issued to India’s Aurobindo in October; one for a sterile facility and one for an API facility. 

> CDMO Catalent has been tapped by China's BeiGene, to manufacture its immuno-oncology drug Brukinsa. Release 

> South Korea and Singapore have signed an agreement to work together and share information GMP inspections. Story 

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

> Ingredient supplier Barentz says that private equity firm Cinven has made an investment that will allow it to expand. Story